These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3057833)

  • 21. Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt).
    Jönsson G; Högberg B; Nilsson T
    Scand J Urol Nephrol; 1977; 11(3):231-8. PubMed ID: 339329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate.
    Edsmyr F; Esposti PL; Andersson L
    Scand J Urol Nephrol Suppl; 1980; 55():139-42. PubMed ID: 6938017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical evaluation of the effectiveness of estracyt and radiation therapy in the treatment of stages II and III prostatic cancer].
    Matveev BP; Figurin KM; Minakova LR; Goikhberg MI; Aslamazov EG
    Urol Nefrol (Mosk); 1986; (2):51-4. PubMed ID: 3521041
    [No Abstract]   [Full Text] [Related]  

  • 24. [Estracyt and radiotherapy in the treatment of prostatic cancer].
    Van Regemorter G; Germeau F
    Acta Urol Belg; 1980 Jan; 48(1):138-48. PubMed ID: 7435350
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of advanced carcinoma of the prostate with Estracyt.
    Nagel R; Kölln CP
    Prog Clin Biol Res; 1976; 6():267-84. PubMed ID: 1023214
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of advanced carcinoma of the prostate with Estracyt (author's transl)].
    Nagel R; Kölln CP
    Med Klin; 1976 Oct; 71(41):1724-8. PubMed ID: 824540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estracyt--clinical experiences.
    Nilsson T
    Scand J Urol Nephrol Suppl; 1980; 55():135-8. PubMed ID: 6938016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of prostatic carcinoma with estramustine phosphate (Estracyt).
    Benson RC
    Wis Med J; 1976 Sep; 75(9):S89-90. PubMed ID: 969557
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of advanced metastasizing carcinoma of the prostate with estracyt (author's transl)].
    Rambausek M; Lutherer S; Terhorst B
    Urologe A; 1981 Jul; 20(4):223-7. PubMed ID: 7196632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Estracyt (estradiol-nitrogen mustard complex)--estramustine binding protein and its specificity].
    Yamanaka H; Imai K; Suzuki T; Yuasa H; Takahashi E
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2106-14. PubMed ID: 6486830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
    Murphy GP; Slack NH; Mittelman A
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
    [No Abstract]   [Full Text] [Related]  

  • 32. Hormonal effects of different doses of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
    Fritjofsson A; Norlén BJ; Högberg B; Rajalakshmi M; Cekan SZ; Diczfalusy E
    Scand J Urol Nephrol; 1981; 15(1):37-44. PubMed ID: 6787701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical studies on serum lipids in the patients with tumor of the prostate gland. 2nd. Report. Changes of serum lipids and lipoprotein fractions during the treatment of estramustine phosphate disodium, hexestrol and diethylstilbestrol 4, 4-diphosphoric ester for the patients with prostatic cancer (author's transl)].
    Yoshida H; Shimada M
    Nihon Hinyokika Gakkai Zasshi; 1980 Jan; 71(1):59-69. PubMed ID: 6155501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Value of estramustine phosphate in the treatment of estrogen-resistant prostatic adenocarcinoma].
    Toulouse J; Jung JL; Bittard M
    J Urol (Paris); 1984; 90(1):27-33. PubMed ID: 6725973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A current review of the clinical experience with Estracyt.
    Murphy GP
    Prog Clin Biol Res; 1987; 243B():221-5. PubMed ID: 3309982
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
    Yamanaka H; Shida K
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):537-44. PubMed ID: 6422861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experiences with estramustinphosphate (Estracyt) in estrogen-resistant metastasizing prostatic cancer].
    Köller A; Lunglmayr G
    Wien Med Wochenschr; 1983; 133(7):179-81. PubMed ID: 6868629
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estracyt--mode of action and clinical experience.
    Hedlund PO
    Prog Clin Biol Res; 1987; 243B():215-9. PubMed ID: 3309981
    [No Abstract]   [Full Text] [Related]  

  • 40. The absorption metabolism, and excretion of Estracyt (NSC 89199) in patients with prostatic cancer.
    Forshell GP; Müntzing J; Ek A; Lindstedt E; Dencker H
    Invest Urol; 1976 Sep; 14(2):128-31. PubMed ID: 972005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.